The European Union drug regulator said on Monday it had not yet received results from large-scale trials on the Covid vaccines being developed by Pfizer and BioNTech and that it was currently assessing earlier data on the quality of the shot.
The European Medicines Agency (EMA) started a rolling review of data from trials on the vaccine in early October.
“We evaluated the first batch of data on the vaccine, which came from laboratory studies (non-clinical data). The Agency is currently assessing a second batch of data which relate to the quality of the vaccine, including data related to its ingredients and the way it is produced,” it said in a statement.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.